Cidara Therapeutics

Cidara Completes 5,000-Patient Enrollment in Phase 2b Universal Flu Prevention Trial, Secures $105M Financing

3 months ago

• Cidara Therapeutics has completed enrollment of 5,000 subjects in its Phase 2b NAVIGATE trial evaluating CD388, a single-dose universal influenza preventative drug. • The company secured $105 million in private placement funding led by Venrock Healthcare Capital Partners, strengthening its financial position for continued drug development. • Due to the severe 2024-25 flu season, Cidara may conduct an early efficacy analysis in the first half of 2025, potentially accelerating the timeline for Phase 3 trials.

Robust Influenza Pipeline Features 120+ Drug Candidates with Novel Approaches to Prevention and Treatment

4 months ago

DelveInsight's latest report reveals over 120 companies actively developing innovative therapies for influenza, including promising candidates like Moderna's mRNA-1010 vaccine and SAB Biotherapeutics' polyclonal antibody treatment. The pipeline showcases diverse therapeutic approaches, from next-generation vaccines to broad-spectrum antivirals, addressing critical needs in influenza prevention and treatment.

Cidara Therapeutics Completes Enrollment in Phase IIb Trial of CD388 for Influenza Prevention

6 months ago

• Cidara Therapeutics has completed enrollment in its Phase IIb NAVIGATE trial, evaluating CD388 for pre-exposure prophylaxis of seasonal influenza. • The trial enrolled 5,000 healthy, unvaccinated adults across clinical sites in the US and UK, assessing the safety and efficacy of CD388. • Participants receive single doses of CD388 (150mg, 300mg, 450mg) or placebo and are monitored for influenza breakthrough cases during the flu season. • CD388, a drug-Fc conjugate, aims to provide long-acting, universal influenza prevention, with potential to address unmet needs in seasonal flu prophylaxis.